Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
-
Narrated by:
-
By:
About this listen
Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics:
- Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00)
- CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06)
- Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative Breast Cancer (21:17)
- Treatment of PIK3CA/PTEN/AKT-Mutated Breast Cancer (31:34)
- Antibody-Drug Conjugates (ADCs) for HR-Positive, HER2-Negative Breast Cancer (38:41)
- ADCs for HER2-Positive Breast Cancer (46:30)
- HER2-Targeting Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer (53:26)
- ADCs for Advanced Triple-Negative Breast Cancer (58:29)
CME information and select publications
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet